CA2901394A1 - Growth differentiation factor (gdf) for treatment of diastolic heart failure - Google Patents

Growth differentiation factor (gdf) for treatment of diastolic heart failure Download PDF

Info

Publication number
CA2901394A1
CA2901394A1 CA2901394A CA2901394A CA2901394A1 CA 2901394 A1 CA2901394 A1 CA 2901394A1 CA 2901394 A CA2901394 A CA 2901394A CA 2901394 A CA2901394 A CA 2901394A CA 2901394 A1 CA2901394 A1 CA 2901394A1
Authority
CA
Canada
Prior art keywords
gdf11
polypeptide
seq
level
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2901394A
Other languages
English (en)
French (fr)
Inventor
Richard T. Lee
Francesco LOFFREDO
James PANCOAST
Matthew STEINHAUSER
Amy Wagers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Brigham and Womens Hospital Inc
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc, Harvard University filed Critical Brigham and Womens Hospital Inc
Publication of CA2901394A1 publication Critical patent/CA2901394A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA2901394A 2012-03-19 2013-03-11 Growth differentiation factor (gdf) for treatment of diastolic heart failure Pending CA2901394A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261612550P 2012-03-19 2012-03-19
US61/612,550 2012-03-19
US201261649962P 2012-05-22 2012-05-22
US61/649,962 2012-05-22
PCT/US2013/030140 WO2013142114A1 (en) 2012-03-19 2013-03-11 Growth differentiation factor (gdf) for treatment of diastolic heart failure

Publications (1)

Publication Number Publication Date
CA2901394A1 true CA2901394A1 (en) 2013-09-26

Family

ID=49223184

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2901394A Pending CA2901394A1 (en) 2012-03-19 2013-03-11 Growth differentiation factor (gdf) for treatment of diastolic heart failure

Country Status (6)

Country Link
US (1) US9434779B2 (enExample)
EP (1) EP2828289B1 (enExample)
JP (1) JP6124986B2 (enExample)
CA (1) CA2901394A1 (enExample)
ES (1) ES2779698T3 (enExample)
WO (1) WO2013142114A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10359425B2 (en) 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
JP5931874B2 (ja) 2010-08-13 2016-06-08 ソマロジック・インコーポレーテッド 膵癌バイオマーカーおよびその使用
SG10201607331WA (en) * 2011-09-30 2016-11-29 Somalogic Inc Cardiovascular risk event prediction and uses thereof
JP2016518357A (ja) * 2013-04-08 2016-06-23 プレジデント アンド フェローズ オブ ハーバード カレッジ 骨格筋幹細胞を若返らせる方法および組成物
EP3881859B1 (en) * 2013-06-11 2024-03-06 President and Fellows of Harvard College Compositions for increasing neurogenesis and angiogenesis
WO2015073396A1 (en) * 2013-11-12 2015-05-21 The Brigham And Women's Hospital, Inc. Growth differentiation factor (gdf) for treatment of diastolic heart failure
EP3142680A4 (en) * 2014-05-16 2018-05-23 Intermune, Inc. Lpa-associated protein and rna expression
WO2016049662A1 (en) * 2014-09-23 2016-03-31 President And Fellows Of Harvard College Methods and compositions for treating age-related disorders
AU2015353767B2 (en) 2014-11-24 2021-09-09 Somalogic Operating Co., Inc. Nucleic acid compounds for binding growth differentiation factor 11
WO2017115789A1 (ja) 2015-12-28 2017-07-06 国立研究開発法人理化学研究所 加齢による生理機能の低下を回復または改善する組成物
CA3010799A1 (en) 2016-01-06 2017-07-13 President And Fellows Of Harvard College Treatment with gdf11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis
WO2019144053A1 (en) * 2018-01-19 2019-07-25 President And Fellows Of Harward College Gdf11 variants and uses thereof
US20200222459A1 (en) * 2019-01-16 2020-07-16 Melvin Barnes System, Method and Compositions for Treating Age-Related Illnesses and Conditions
JP2022001603A (ja) * 2021-10-14 2022-01-06 功 加治佐 自分由来ｉＰＳ若い血液応用ＧＤＦ１１分子コーティング若返り経口不老不死薬９
CN114989310B (zh) * 2022-06-20 2024-11-19 深圳先进技术研究院 一种嵌合抗原受体、表达嵌合抗原受体的巨噬细胞及应用
CN115212299A (zh) * 2022-06-21 2022-10-21 深圳先进技术研究院 Car-t和car-m联用在制备抗肿瘤药物中的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4612302A (en) 1983-11-14 1986-09-16 Brigham And Women's Hospital Clinical use of somatostatin analogues
US4684620A (en) 1984-09-04 1987-08-04 Gibson-Stephens Neuropharmaceuticals, Inc. Cyclic polypeptides having mu-receptor specificity
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4853371A (en) 1986-06-17 1989-08-01 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
PT698094E (pt) * 1993-05-12 2004-05-31 Inst Genetics Llc Composicoes de bmp-11
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6008434A (en) 1994-07-08 1999-12-28 Johns Hopkins University School Of Medicine Growth differentiation factor-11 transgenic mice
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
EP0985149A1 (en) 1997-05-30 2000-03-15 Creative Biomolecules, Inc. Methods for evaluating tissue morphogenesis and activity
US20030170213A1 (en) * 1998-01-23 2003-09-11 Marc F. Charette Methods and compositions for enhancing cognitive function using morphogenic proteins
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
US20060078532A1 (en) * 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of Atherosclerosis, Peripheral vascular disease, Coronary artery disease, aging and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
WO2004073633A2 (en) * 2003-02-14 2004-09-02 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for modulating the development of stem cells
NZ529860A (en) 2003-11-28 2006-10-27 Ovita Ltd Muscle growth regulator mighty and use in promoting muscle mass and treating muscle wasting diseases
EP1858546A4 (en) 2005-03-04 2009-03-04 Biorexis Pharmaceutical Corp MODIFIED TRANSFERRINFUSION PROTEINS
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
WO2007142818A2 (en) 2006-05-17 2007-12-13 Stryker Corporation Use of a soluble morphogenic protein complex for treating cartilage defects
TWI573802B (zh) * 2007-03-06 2017-03-11 安美基公司 變異之活動素受體多肽及其用途
EP3141905B1 (en) 2008-03-27 2019-03-06 Promega Corporation Protein labeling with cyanobenzothiazole conjugates

Also Published As

Publication number Publication date
JP2015512387A (ja) 2015-04-27
US20150045297A1 (en) 2015-02-12
EP2828289B1 (en) 2020-02-26
US9434779B2 (en) 2016-09-06
EP2828289A1 (en) 2015-01-28
ES2779698T3 (es) 2020-08-18
EP2828289A4 (en) 2016-01-06
JP6124986B2 (ja) 2017-05-10
WO2013142114A1 (en) 2013-09-26

Similar Documents

Publication Publication Date Title
EP2828289B1 (en) Growth differentiation factor (gdf) 11 for treatment of age-related cardiovascular condition
US11612639B2 (en) Methods and compositions for rejuvenating skeletal muscle stem cells
US20200317767A1 (en) Growth differentiation factor (gdf) for treatment of diastolic heart failure
US11725033B2 (en) GDF11 variants and uses thereof
Zhou et al. Histamine-4 receptor antagonist JNJ7777120 inhibits pro-inflammatory microglia and prevents the progression of Parkinson-like pathology and behaviour in a rat model
EP2763688B1 (en) Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome
WO2016118859A1 (en) Compositions and methods for selectively depleting senescent cells comprising flip
WO2012159107A1 (en) Inhibition of renal fibrosis
US20160287667A1 (en) Methods and compositions for rejuvenating neuromuscular junctions
Ding et al. Cellular delivery of relaxin-2 mRNA as a potential treatment for kidney fibrosis
US11529391B2 (en) Reversing deficient hedgehog signaling restores deficient skeletal regeneration
US20220062299A1 (en) Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
US20240382561A1 (en) Glucoregulatory compound, composition and uses thereof
US20250129093A1 (en) Compositions and methods relating to atp/p2x7r signaling inhibition
HK40091706A (zh) 葡萄糖调节化合物、其组合物和其用途
Wang et al. pathways, mTORC1 and Abl, in β Noncanonical TGF

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180213

EEER Examination request

Effective date: 20180213

EEER Examination request

Effective date: 20180213

EEER Examination request

Effective date: 20180213

EEER Examination request

Effective date: 20180213

EEER Examination request

Effective date: 20180213